Evaxion Biotech A/S

Equities

EVAX

US29970R2040

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:00 17/07/2024 am IST			5-day change	1st Jan Change
3.14 ^USD	-0.29%		-5.71%	-54.21%

16/07	European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	MT
08/07	European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading	MT

Evaxion Receives Phase IIb Go-Ahead from FDA

January 16, 2023 at 12:45 pm IST

Evaxion Biotech started 2022 with a green light from the Australian authorities to conduct a phase IIb study with lead drug candidate EVX-01 in metastatic melanoma. 2023 for the Danish immunotherapy company begins with the FDA-approval to expand the phase IIb study to the US. BioStock contacted CEO Per Norlén to learn more about what this means for the project.

Latest news about Evaxion Biotech A/S

European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading	16/07	MT
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading	08/07	MT
Evaxion Biotech A/S Announces Resignation of Niels Iversen as A Director from the Board of Directors and All Board Committees	04/07	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	03/07	MT
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	27/06	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading	25/06	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	24/06	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher	21/06	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading	18/06	MT
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading	17/06	MT
Evaxion Biotech A/S Announces Publication of Data from Its Phase 1 Dose Escalation Study of Its Lead Personalized Cancer Vaccine, EVX-01	17/06	CI
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading	11/06	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	04/06	MT
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading	03/06	MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading	29/05	MT
Earnings Flash (EVAX) EVAXION BIOTECH Reports Q1 Revenue $51,000	28/05	MT
Evaxion Biotech A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	28/05	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower	24/05	MT
Evaxion Biotech Plans to Unveil 'Positive' Data From Phase 2 Study of Advanced Melanoma Combination Treatment	24/05	MT
Evaxion Biotech A/S to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024	24/05	CI
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	24/05	MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading	22/05	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading	21/05	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Wednesday Trading	15/05	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher	13/05	MT

Chart Evaxion Biotech A/S

Duration

Period

More charts

Company Profile

Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.149 USD

Average target price

11.75 USD

Spread / Average Target

+273.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EVAXION BIOTECH A/S	-54.21%	17.04M
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B

Other Biotechnology & Medical Research